Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2013
Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trialsA J Templeton, F E Vera-Badillo, L Wang, et al.
ESMO Open|March 19, 2025
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patientsS Gupta, M A Climent Duran, S S Sridhar, et al.
Investigational New Drugs|May 19, 2015
A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195B J Eigl, S North, E Winquist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 25, 2014
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancerR Leibowitz-Amit, A J Templeton, A Omlin, et al.
Clinical Genitourinary Cancer|July 5, 2014
Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial designG R Pond, J Bellmunt, J E Rosenberg, et al.
ESMO Open|December 6, 2024
Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trialJ E Rosenberg, M D Galsky, T Powles, et al.
ESMO Open|August 12, 2025
Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinomaM S van der Heijden, T Powles, S Gupta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2021
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trialM Annala, S Fu, J V W Bacon, et al.
European Urology Focus|August 11, 2020
Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International ConsortiumMaria Carmen Mir, Michele Marchioni, Homi Zargar, et al.
World Journal of Urology|June 9, 2018
Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomyN Vasdev, H Zargar, J P Noël, et al.
Pageof 2